<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4856">
  <stage>Registered</stage>
  <submitdate>2/03/2015</submitdate>
  <approvaldate>2/03/2015</approvaldate>
  <nctid>NCT02381886</nctid>
  <trial_identification>
    <studytitle>A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations</studytitle>
    <scientifictitle>A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CIDH305X2101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Malignancies That Harbor IDHR132 Mutations</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IDH305

Experimental: IDH305 - 


Treatment: drugs: IDH305


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incident rate of dose limiting toxicities (DLTs) - To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE)</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events (AEs) - To characterize the safety and tolerability of IDH305</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PK parameters (AUC, Cmax, Tmax) - To characterize the PK profile of IDH305</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes of 2-hydroxyglutarate concentration in patient specimens - To characterize the PD profile of IDH305</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate (ORR) - To assess any preliminary anti-tumor activity of IDH305</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of serious adverse events (SAE) - To characterize the safety and tolerability of IDH305</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Documented IDH1R132-mutant tumors

          -  ECOG performance status = 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with
             the exception of glioma patients)

          -  Medical conditions that would prevent the patient's participation in the clinical
             study due to safety concerns or compliance with clinical study procedures such as the
             presence of other clinically significant cardiac, respiratory, gastrointestinal,
             renal, hepatic or neurological disease.

          -  Acute Promyelocytic Leukemia

          -  Women who are pregnant or lactating

        Other protocol-defined Inclusion/Exclusion may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>6/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <anticipatedlastvisitdate>26/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Melbourne</hospital>
    <hospital>Novartis Investigative Site - Parkville</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132
      mutations.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02381886</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>